Therapy-related myelodysplastic syndrome
Information
- Disease name
- Therapy-related myelodysplastic syndrome
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02658487 | Active, not recruiting | Phase 2 | Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia | March 2016 | September 2024 |
| NCT05316701 | Active, not recruiting | Phase 3 | Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies | June 21, 2022 | April 2027 |
| NCT01885689 | Active, not recruiting | Phase 2 | Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia | February 10, 2014 | December 30, 2024 |
| NCT03096782 | Completed | Phase 2 | Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma | October 13, 2017 | September 20, 2022 |
| NCT01823198 | Completed | Phase 1/Phase 2 | Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies | June 11, 2013 | May 10, 2022 |
| NCT02960646 | Completed | Phase 1 | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | January 18, 2017 | February 13, 2023 |
| NCT03359460 | Completed | Phase 1 | Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome | December 1, 2017 | November 17, 2019 |
| NCT05379166 | Recruiting | Phase 2 | Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome | June 23, 2022 | December 31, 2024 |
| NCT05292664 | Recruiting | Phase 1 | Venetoclax Basket Trial for High Risk Hematologic Malignancies | March 29, 2023 | April 2, 2027 |
| NCT04160052 | Recruiting | Phase 1/Phase 2 | Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome | October 1, 2019 | December 31, 2025 |
| NCT04550442 | Recruiting | Phase 1/Phase 2 | Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | September 4, 2020 | May 11, 2025 |
| NCT02727803 | Recruiting | Phase 2 | Personalized NK Cell Therapy in CBT | May 19, 2016 | May 31, 2025 |
| NCT03272633 | Terminated | Early Phase 1 | Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies | October 26, 2020 | September 22, 2022 |
| NCT01619761 | Unknown status | Phase 1 | NK Cells in Cord Blood Transplantation | May 3, 2013 | November 2021 |